Treatment of Metastatic Clear-Cell Renal Cell Carcinoma in IMDC Intermediate- or Poor-Risk Patients

Clinical Scenario

This protocol addresses metastatic clear-cell renal cell carcinoma in patients classified as intermediate- or poor-risk by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. IMDC risk stratification directly determines the recommended treatment pathway for this population.

Treatment Approach

For this risk category, the treatment algorithm includes VEGF-targeted tyrosine kinase inhibitor therapy as one component of the approach. The complete regimen options, sequencing, and criteria for this population are specified in the full protocol.

Dosing, full regimen options, and treatment sequencing are available in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Offer nivolumab plus ipilimumab, pembrolizumab plus axitinib, lenvatinib plus pembrolizumab or nivolumab and cabozantinib to patients with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate- or poor-risk disease.

Offer cabozantinib or other VEGF-TKI as second-line therapy to patients refractory to nivolumab plus ipilimumab or axitinib plus pembrolizumab or cabozantinib plus nivolumab or lenvatinib plus pembrolizumab.

View source ↗